EUVIMEDEUVIMED entdecken
Crossref

Illuminating the mutational spectrum of pediatric myeloproliferative neoplasms

Stephen E. Langabeer

Biomedical Genetics and Genomics · 2016

DOI: 10.15761/bgg.1000114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Genetics and Genomics, 2016. Verfasst von Stephen E. Langabeer.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Received: August 14, 2016; Accepted: August 25, 2016; Published: August 27, 2016 The myeloproliferative neoplasms (MPN) are clonal, hematopoietic stem cell-derived diseases characterised by bone marrow proliferation of one or more of the myeloid cell lineages with the main subtypes being polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The diagnosis and classification of these diseases is dependent on clinical, hematological, histo-morphological and increasingly, on molecular genetic findings [1]. In adults, the most commonly acquired mutation associated with MPN is the JAK2 V617F, occurring in >95% of PV cases and in 50 60% of ET and PMF patients. This mutation disrupts the function of the intracellular JAK2 molecule that is required for normal hematopoietic cytokine signalling and has become a target for therapeutic intervention [2]. Alternative mutations of JAK2 within exon 12 can be detected in the majority of those remaining V617F-negative PV patients [3]. Several other genetic abnormalities have been described in MPN which occur at a much lower frequency than the JAK2 V617F. Mutations in MPL exon 10, which encodes the receptor for thrombopoietin, a major regulator of megakaryocyte and platelet development, are present in approximately 5% and 3% of PMF and ET patients respectively [4]. Recent whole exome sequencing studies of adult MPN patients have led to the discovery of insertion and/or deletion mutations in exon 9 of CALR, a gene that encodes the endoplasmic reticulum-associated, calcium binding protein, calreticulin. These disease driving mutations of CALR result in a frame shift of the coding sequence, altered amino acid composition of the translated protein, and loss of the endoplasmic reticulum retention motif. CALR mutations do not occur in PV patients but are present in up to 80% of ET and PMF patients who are JAK2 V617F-and MPL-mutation negative [5]. Approximately 10% of adult ET and PMF patients have no evidence of these three driver mutation types and are termed “triple-negative” MPN. Supplementary “passenger” mutations may be acquired that can influence the initiation and evolution of the disease, however these mutations are not specific for MPN as they are also present in other myeloid malignancies such as myelodysplastic syndromes and acute myeloid leukemia [6].

Zitieren

APA

Langabeer, S. E. (2016). Illuminating the mutational spectrum of pediatric myeloproliferative neoplasms. Biomedical Genetics and Genomics. https://doi.org/10.15761/bgg.1000114

Vancouver

Langabeer SE. Illuminating the mutational spectrum of pediatric myeloproliferative neoplasms. Biomedical Genetics and Genomics. 2016. doi:10.15761/bgg.1000114

BibTeX
@article{Langabeer2016,
  author = {Langabeer, Stephen E.},
  title = {Illuminating the mutational spectrum of pediatric myeloproliferative neoplasms},
  journal = {Biomedical Genetics and Genomics},
  year = {2016},
  doi = {10.15761/bgg.1000114}
}
Kostenlos starten →